South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 489.26 billion. The enterprise value is 124.20 billion.
| Market Cap | 489.26B |
| Enterprise Value | 124.20B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
BioNote has 101.19 million shares outstanding. The number of shares has decreased by -0.69% in one year.
| Current Share Class | 101.19M |
| Shares Outstanding | 101.19M |
| Shares Change (YoY) | -0.69% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 59.12% |
| Owned by Institutions (%) | 0.28% |
| Float | 13.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.87 |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | 11.76 |
| P/OCF Ratio | 10.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.07, with an EV/FCF ratio of 2.98.
| EV / Earnings | n/a |
| EV / Sales | 0.98 |
| EV / EBITDA | 4.07 |
| EV / EBIT | 6.02 |
| EV / FCF | 2.98 |
Financial Position
The company has a current ratio of 18.53, with a Debt / Equity ratio of 0.00.
| Current Ratio | 18.53 |
| Quick Ratio | 17.03 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 0.08 |
| Interest Coverage | 102.65 |
Financial Efficiency
Return on equity (ROE) is -7.79% and return on invested capital (ROIC) is 1.74%.
| Return on Equity (ROE) | -7.79% |
| Return on Assets (ROA) | 0.77% |
| Return on Invested Capital (ROIC) | 1.74% |
| Return on Capital Employed (ROCE) | 1.30% |
| Weighted Average Cost of Capital (WACC) | 7.66% |
| Revenue Per Employee | 424.18M |
| Profits Per Employee | -421.76M |
| Employee Count | 298 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, BioNote has paid 11.96 billion in taxes.
| Income Tax | 11.96B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.18% in the last 52 weeks. The beta is 0.62, so BioNote's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -15.18% |
| 50-Day Moving Average | 4,657.30 |
| 200-Day Moving Average | 5,185.95 |
| Relative Strength Index (RSI) | 56.00 |
| Average Volume (20 Days) | 76,003 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 126.41 billion and -125.69 billion in losses. Loss per share was -1,246.51.
| Revenue | 126.41B |
| Gross Profit | 71.39B |
| Operating Income | 20.63B |
| Pretax Income | -113.73B |
| Net Income | -125.69B |
| EBITDA | 30.52B |
| EBIT | 20.63B |
| Loss Per Share | -1,246.51 |
Balance Sheet
The company has 368.27 billion in cash and 3.21 billion in debt, with a net cash position of 365.06 billion or 3,607.65 per share.
| Cash & Cash Equivalents | 368.27B |
| Total Debt | 3.21B |
| Net Cash | 365.06B |
| Net Cash Per Share | 3,607.65 |
| Equity (Book Value) | 1.55T |
| Book Value Per Share | 15,383.18 |
| Working Capital | 413.62B |
Cash Flow
In the last 12 months, operating cash flow was 45.56 billion and capital expenditures -3.94 billion, giving a free cash flow of 41.61 billion.
| Operating Cash Flow | 45.56B |
| Capital Expenditures | -3.94B |
| Depreciation & Amortization | 9.89B |
| Net Borrowing | -1.41B |
| Free Cash Flow | 41.61B |
| FCF Per Share | 411.21 |
Margins
Gross margin is 56.48%, with operating and profit margins of 16.32% and -99.43%.
| Gross Margin | 56.48% |
| Operating Margin | 16.32% |
| Pretax Margin | -89.97% |
| Profit Margin | -99.43% |
| EBITDA Margin | 24.14% |
| EBIT Margin | 16.32% |
| FCF Margin | 32.92% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 4.11%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 4.11% |
| Dividend Growth (YoY) | 14.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.69% |
| Shareholder Yield | 4.80% |
| Earnings Yield | -25.69% |
| FCF Yield | 8.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 6.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.77 |
| Piotroski F-Score | 5 |